[{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Oncologie","pharmaFlowCategory":"D","amount":"$306.0 million","upfrontCash":"$4.0 million","newsHeadline":"Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Navicixizumab","moa":"DLL4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mereo BioPharma Group","amount2":0.31,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.31,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ Oncologie","highestDevelopmentStatusID":"6","companyTruncated":"Mereo BioPharma Group \/ Oncologie"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Announces Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta and Provides Update on Regulatory Progress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Setrusumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mereo BioPharma Announces Completion of $70 Million Private Placement and Plans to Develop Etigilimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Private Placement","leadProduct":"Etigilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ OrbiMed"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b\/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Alvelestat","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Setrusumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b\/2 study for Etigilimab (Anti-TIGIT)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Etigilimab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","amount":"$304.0 million","upfrontCash":"$50.0 million","newsHeadline":"Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Setrusumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0.29999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Ultragenyx","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Ultragenyx"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Receives U.S. Orphan Drug Designation for Alvelestat in the Treatment of Alpha-1 Antitrypsin Deficiency","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Alvelestat","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo Reports Interim Data from ACTIVATE Phase 1b\/2 Study of Etigilimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Etigilimab","moa":"TIGIT protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from ASTRAEUS Phase 2 Study of Alvelestat","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Alvelestat","moa":"Leucocyte elastase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b\/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Etigilimab","moa":"TIGIT protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma To Present Data Update for the Phase 1b\/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Etigilimab","moa":"TIGIT protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Setrusumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ Mereo BioPharma Group","highestDevelopmentStatusID":"9","companyTruncated":"Mereo BioPharma Group \/ Mereo BioPharma Group"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b\/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Etigilimab","moa":"TIGIT protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Alvelestat","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Alvelestat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Alvelestat","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2\/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Setrusumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ Mereo BioPharma Group","highestDevelopmentStatusID":"10","companyTruncated":"Mereo BioPharma Group \/ Mereo BioPharma Group"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2\/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Setrusumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ Mereo BioPharma Group","highestDevelopmentStatusID":"10","companyTruncated":"Mereo BioPharma Group \/ Mereo BioPharma Group"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mereo BioPharma Prices $50 Million Direct Offering of American Depository Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Setrusumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Jefferies"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx & Mereo BioPharma: New Phase 2 Data on Setrusumab in Osteogenesis Imperfecta","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Setrusumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ Mereo BioPharma Group","highestDevelopmentStatusID":"9","companyTruncated":"Mereo BioPharma Group \/ Mereo BioPharma Group"}]
Find Clinical Drug Pipeline Developments & Deals by Mereo BioPharma Group
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Market Place
Reset All
